AdvNanoT develops SirPlux™ Duo, a drug-coated balloon that utilizes biodegradable nanoparticles to deliver Sirolimus and Paclitaxel directly to arterial lesions, enhancing drug retention and cellular uptake. This technology addresses the challenges of atherosclerosis and blockage in coronary and peripheral artery diseases by providing stent-like patency without the complications associated with traditional stents.
Funding
$19.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Coronary and peripheral artery diseases are characterized by arterial lesions that cause atherosclerosis and blockage, often requiring stents to maintain patency. Traditional stents, however, can lead to complications such as restenosis and long-term burden within the vessel. Effective drug delivery to the lesion site remains a challenge, limiting the efficacy of current treatments.
Solution
AdvNanoT's SirPlux™ Duo Drug-Coated Balloon (DCB) addresses these challenges by delivering a combination of Sirolimus and Paclitaxel directly to arterial lesions using a proprietary nanoparticle drug delivery platform. This platform enables sustained, localized release of the two synergistic drugs, inhibiting cell growth at a higher potency but lower overall dosage. The biodegradable nanoparticles enhance drug retention and cellular uptake, providing stent-like patency without the long-term complications associated with traditional stents. The drug-agnostic nanoparticle platform allows for potential use with single or multiple drug combinations across various applications.
Target Audience
The primary target audience includes interventional cardiologists and vascular surgeons treating patients with coronary artery disease (CAD) and peripheral artery disease (PAD).
Features
- Dual-drug delivery of Sirolimus and Paclitaxel for synergistic antiproliferative effects.
- Biodegradable nanoparticle technology for enhanced drug retention and cellular uptake at the lesion site.
- Sustained drug release profile for long-term inhibition of cell growth.
- Lower drug dosage compared to traditional drug-coated balloons, minimizing systemic exposure.
- Stent-like patency without the complications associated with permanent stent implantation.
- Drug-agnostic nanoparticle platform adaptable to various single or multiple drug combinations.
- Potential applications beyond cardiovascular, including neurology, ENT, and orthopedics.